News
We report 5-year efficacy and safety outcomes from the phase III KEYNOTE-407 study (ClinicalTrials.gov identifier: NCT02775435).Eligible patients with previously untreated, metastatic squamous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback